Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa.
Abstract
We describe the successful use of rituximab for the treatment of IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. To our knowledge, this is the first reported case in the literature.
Citations
Altmetric:
Date
2022-06-09
Type
Article
Subject
Oncology. Pathology., Nephrology/Renal medicine, Elderly care.
Collections
Citation
Hunjan MK, Bardhan A, Harper N, Langman G, Ajayi B, Suresh V, Heagerty AHM. Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol. 2022 Aug;47(8):1588-1590. doi: 10.1111/ced.15228. Epub 2022 Jun 9
Journal / Source Title
Clinical and Experimental Dermatology
DOI
10.1111/ced.15228
PMID
35426452
Publisher
Oxford University Press
Publisher’s URL
https://academic.oup.com/ced